UA118120C2 - Макроциклічні похідні піридину - Google Patents

Макроциклічні похідні піридину

Info

Publication number
UA118120C2
UA118120C2 UAA201611003A UAA201611003A UA118120C2 UA 118120 C2 UA118120 C2 UA 118120C2 UA A201611003 A UAA201611003 A UA A201611003A UA A201611003 A UAA201611003 A UA A201611003A UA 118120 C2 UA118120 C2 UA 118120C2
Authority
UA
Ukraine
Prior art keywords
compounds
macrocylic
pyridine derivatives
inhibitory activity
present
Prior art date
Application number
UAA201611003A
Other languages
English (en)
Ukrainian (uk)
Inventor
Ґастон Станіслас Марсела Дилс
Бруно Схунтьєс
Матіас Люк Еме Версель
Дидьє Жан-Клод Бертло
Марк Вілемс
Марсель В'єєвуа
Франсуа Марія Сомен
Бертольд Вробловскі
Лівен Мерпул
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of UA118120C2 publication Critical patent/UA118120C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UAA201611003A 2014-04-03 2015-04-02 Макроциклічні похідні піридину UA118120C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163442 2014-04-03
EP14183823 2014-09-05
PCT/EP2015/057401 WO2015150557A1 (en) 2014-04-03 2015-04-02 Macrocylic pyridine derivatives

Publications (1)

Publication Number Publication Date
UA118120C2 true UA118120C2 (uk) 2018-11-26

Family

ID=52781118

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201611003A UA118120C2 (uk) 2014-04-03 2015-04-02 Макроциклічні похідні піридину

Country Status (22)

Country Link
US (1) US20170022201A1 (enExample)
EP (1) EP3126365B1 (enExample)
JP (1) JP6420362B2 (enExample)
KR (1) KR102390274B1 (enExample)
CN (1) CN106132964B (enExample)
AU (1) AU2015239100B2 (enExample)
BR (1) BR112016022700B1 (enExample)
CA (1) CA2942751C (enExample)
CL (1) CL2016002495A1 (enExample)
EA (1) EA029758B1 (enExample)
ES (1) ES2665797T3 (enExample)
IL (1) IL248001B (enExample)
MA (1) MA39823A (enExample)
MX (1) MX369799B (enExample)
MY (1) MY185500A (enExample)
NZ (1) NZ725406A (enExample)
PE (1) PE20161365A1 (enExample)
PH (1) PH12016501962B1 (enExample)
SG (1) SG11201608241UA (enExample)
UA (1) UA118120C2 (enExample)
WO (1) WO2015150557A1 (enExample)
ZA (1) ZA201606768B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10407442B2 (en) 2015-09-24 2019-09-10 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
AU2017219846B2 (en) 2016-02-19 2021-05-13 Sprint Bioscience Ab 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
LT3416957T (lt) 2016-02-19 2020-11-25 Sprint Bioscience Ab 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui
IL316954A (en) 2017-02-28 2025-01-01 Morphic Therapeutic Inc (Alpha-V)(beta-6)integrin inhibitors
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
ES2900199T3 (es) 2017-03-28 2022-03-16 Bayer Ag Novedosos compuestos macrocíclicos inhibidores de PTEFB
WO2018177889A1 (en) 2017-03-28 2018-10-04 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
US20200190083A1 (en) * 2017-06-22 2020-06-18 Cyclenium Pharma Inc. Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same
CN116589461A (zh) 2017-08-23 2023-08-15 思普瑞特生物科学公司 氮杂吲哚基吡啶酮化合物和二氮杂吲哚基吡啶酮化合物
IL302293A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Pyridinamine-pyridone and pyrimidinamine-pyridone compounds
IL302077A (en) 2017-08-23 2023-06-01 Sprint Bioscience Ab Morpholinylpyridone compounds
EP4056556A1 (en) 2017-08-23 2022-09-14 Sprint Bioscience AB Pyridylpyridone compounds
WO2020047208A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
UY38353A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibición de integrina alfavbeta6
EP4013762A1 (en) * 2019-08-16 2022-06-22 Inflazome Limited Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors
CN113845521B (zh) * 2021-08-31 2024-06-18 中原工学院 水相中光催化一锅法合成咪唑并含氮杂环肼类衍生物的方法
CN115260128B (zh) * 2022-09-21 2022-12-09 苏州凯瑞医药科技有限公司 一种新型jak抑制剂关键中间体的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001051125A1 (en) * 2000-01-12 2001-07-19 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2004078682A2 (en) * 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
EP1697384B1 (en) 2003-12-18 2008-04-02 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
ES2335216T3 (es) 2003-12-18 2010-03-23 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolina con actividad antiproliferativa.
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US8778919B2 (en) * 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
EP1951729B1 (en) * 2005-11-16 2014-06-25 Cell Therapeutics, Inc. Oxygen linked pyrimidine derivatives
CA2687909C (en) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
US8318731B2 (en) 2007-07-27 2012-11-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
EP2283024B1 (en) * 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
KR20110031318A (ko) 2008-06-13 2011-03-25 노파르티스 아게 Ia 심부전 및 암 치료에 유용한 단백질 키나제 d 억제제로서의 2,4'-비피리디닐 화합물

Also Published As

Publication number Publication date
JP2017509685A (ja) 2017-04-06
SG11201608241UA (en) 2016-10-28
ES2665797T3 (es) 2018-04-27
BR112016022700B1 (pt) 2022-01-11
PE20161365A1 (es) 2016-12-17
JP6420362B2 (ja) 2018-11-07
MY185500A (en) 2021-05-19
PH12016501962A1 (en) 2017-01-09
EP3126365B1 (en) 2018-01-10
KR102390274B1 (ko) 2022-04-22
MX2016012994A (es) 2016-12-07
AU2015239100A1 (en) 2016-09-29
MX369799B (es) 2019-11-21
EA201692000A1 (ru) 2017-01-30
IL248001B (en) 2018-11-29
CA2942751A1 (en) 2015-10-08
US20170022201A1 (en) 2017-01-26
CA2942751C (en) 2023-03-21
BR112016022700A2 (enExample) 2017-08-15
MA39823A (fr) 2018-01-09
CN106132964B (zh) 2019-07-19
ZA201606768B (en) 2018-11-28
NZ725406A (en) 2022-08-26
AU2015239100B2 (en) 2019-06-27
EA029758B1 (ru) 2018-05-31
KR20160140739A (ko) 2016-12-07
EP3126365A1 (en) 2017-02-08
PH12016501962B1 (en) 2017-01-09
KR102390274B9 (ko) 2023-03-03
WO2015150557A1 (en) 2015-10-08
CL2016002495A1 (es) 2017-02-24
CN106132964A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
MX369799B (es) Derivados de piridina macrociclicos.
PH12016501963B1 (en) Macrocyclic pyrimidine derivatives
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
PH12017501191B1 (en) Quinazoline derivatives used to treat hiv
PH12017501921A1 (en) Novel compounds
MY198472A (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
MD20170016A2 (ro) Compuşi aminopirimidinici ca inhibitori JAK
PH12018500610B1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
PH12019500731A1 (en) Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors
PH12016501462A1 (en) Neprilysin inhibitors
PH12018500626A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
MX2016009794A (es) Derivado de sulfonamida heterociclico y medicina que comprende el mismo.
MX367914B (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirazina sustituidos y derivados de 5,6,7,8-tetrahidro-4h-pirazolo[1,5-a][1 ,4]diazepina como inhibidores de ros1.
MX367913B (es) Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y 2,3-dihidro-1h-imidazo[1,2-b]pirazol sustituidos como inhibidores de ros1.
EA032927B1 (ru) Производные гидроксиалкилпиперазина в качестве модуляторов cxcr3 рецептора
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.